The clinical features, cytogenetics and response to treatment have been examined in 180 infants (aged Ͻ1 year) with acute leukaemia; 118 with acute lymphoblastic leukaemia (ALL) and 62 with acute myeloid leukaemia (AML). Comparison of clinical features showed no difference in age or sex distribution between infants with ALL and AML but infants with ALL tended to have higher leucocyte counts at presentation. Cytogenetic abnormalities involving 11q23 were found in 66% of ALL and 35% of AML cases, the commonest, t(4;11) being found only in ALL. The other recognised 11q23 translocations were found in both types of leukaemia. Few patients had the common cytogenetic abnormalities associated with ALL in older children and few with AML had good risk abnormalities. Four year eventfree survival 60% cf 30% (P = 0.001) and survival 65% cf 41% (P = 0.007) were significantly better in AML than ALL. These results were due to a lower risk of relapse 27% cf 62% at four years. Superior event-free survival was also seen in the subgroup of patients with 11q23 abnormalities and AML (55% cf 23%). The reasons for superior response in AML are unknown but may be related to the intensity of treatment, lineage of the leukaemia or other as yet unidentified factors. Leukemia (2002) 16, 776-784.
Introduction
Acute leukaemia in infancy is rare, although its epidemiology and biology command increasing interest. 1 Despite the fact that both lymphoblastic (ALL) and myeloid leukaemia (AML) share certain characteristics, most notably frequent monocytic differentiation and cytogenetic abnormalities involving the MLL gene at chromosome band 11q23 treatment strategies for infant AML and ALL differ. It remains uncertain whether there is a true difference in outcome between ALL and AML in infancy, particularly when comparisons of cases with similar cytogenetic abnormalities are made.
We describe here the clinical features and cytogenetic findings in infants under 1 year of age with ALL and AML who have been treated on recent UK Medical Research Council (MRC) protocols. The detailed results of all treatment protocols have been reported elsewhere. [2] [3] [4] The aim of this paper is to review the clinical features and pattern of cytogenetic abnormalities and to compare the outcome in the two types of infant leukaemia.
Patients and methods
The patients included in this study are infants under 1 year at diagnosis who had been treated on two consecutive protocols for ALL and AML, respectively. Infants with ALL were treated on the MRC pilot protocol 2 or a subsequent modification 3 and had been diagnosed between mid-1987 and the end of 1999. Those with myeloid leukaemia had been treated on the MRC AML10 protocol 1988-1995 5 or its successor AML12 4 between 1995 and 1999. All protocols and associated studies had been reviewed by local research ethics committees and informed consent had been obtained from all parents or guardians.
Diagnosis
The diagnosis of ALL or AML was based on standard morphological criteria, supplemented by cytochemistry and immunophenotyping as described elsewhere. 6 A panel of three haematologists performed central morphological review. 7 One infant was originally classified as AML and treated on AML12 but on subsequent morphological and immunological review at diagnosis and relapse was re-classed as ALL; his clinical and cytogenetic information has been included in the group with ALL.
Cytogenetics
Cytogenetic analysis was carried out on diagnostic bone marrow samples in the regional cytogenetics laboratories and the results from the pilot infant ALL protocol were reviewed as described elsewhere. 8 Karyotypic information from patients treated on this protocol was limited to the main chromosomal abnormalities, there was no information on chromosome numbers or additional chromosomal changes for detailed analyses to be made. The cytogenetic findings of the ALL patients from the modified protocol and those with AML were reviewed centrally by the Leukaemia Research Fund/UK Cancer Cytogenetics Group Karyotype Database in ALL 9 and the Childhood AML Cytogenetics Database. Karyotypes were described according to the International System of Human Cytogenetic Nomenclature (ISCN). 10 Fluorescence in situ hybridisation (FISH) to determine the presence of MLL rearrangements was carried out on a small number of cases, either in the regional laboratories or at the Database. A single colour probe, which spans the breakpoint of MLL (Appligene-Oncor, Edinburgh, UK), was hybridised to interphase cells. As a result of a translocation involving MLL the probe splits between the two derived chromosomes. Thus, a positive result is indicated by three MLL signals rather than the two observed in a normal cell.
Treatment
The treatment schedules have been described in detail elsewhere and are compared in outline in AML received four or five courses of high-dose therapy including anthracyclines, cytarabine and etoposide. CNS-directed treatment comprised injections of triple intrathecal chemotherapy at the start of three of the treatment courses with additional intrathecal therapy for children with initial CNS involvement. The total duration of treatment was 5-6 months. The protocol for ALL included anthracyclines during induction, early intensification with etoposide and cytarabine, and subsequent treatment with the identical mitozantrone/ cytarabine combination used in AML. Children with ALL also received high-dose MTX for CNS protection, extended outpatient-based delayed intensification, and continuing (maintenance) therapy with oral mercaptopurine, methotrexate, and prednisolone vincristine reinforcements for a total of 2 years. A minority of patients in both categories were treated with high-dose chemotherapy and autologous (ABMT) or allogeneic bone marrow transplantation (BMT). Patients with AML were eligible for BMT if a histocompatible sibling donor was identified and if not were eligible for randomisation. In AML 10, the randomisation was to a fifth course of treatment with high-dose chemotherapy and ABMT or to stop treatment. In AML 12, patients were randomised to receive four or five courses of treatment. AML12 patients with good risk cytogenetics were not eligible for BMT but were randomised. Five children with AML had received high-dose therapy and ABMT and 11 BMT. Seven BMT were from a histocompatible sibling. Four children in AML12 received BMT from alternative donors (three from a matched unrelated donor and one from a mismatched family donor) although this was not specified in the protocol. The first infant ALL protocol permitted ABMT in first remission and in both BMT was allowed for children with 11q23 abnormalities. Seven infants with ALL received ABMT in first remission and 14 transplants from a sibling or matched unrelated donor in first remission. The results of all analyses so far in both AML and ALL have not suggested any overall advantage for high-dose therapy and bone marrow transplanLeukemia tation and thus event-free survival (EFS) and overall survival data are combined for BMT and chemotherapy.
Statistical analysis
Comparison of clinical features and the remission rate was performed using 2 test and the Mantel-Haenzel test for trend. Kaplan-Meier curves of survival, event-free survival (EFS), relapses and remission deaths were derived using the SUREAL package (W Gregory, personal communication) and compared using the log rank test. 11 Confidence intervals were calculated at the 95% confidence level. All P values are two tailed. All patients have been followed up until January 2001. Event-free survival is defined as the time from diagnosis to either failure to remit, relapse or death in remission, censoring at 1 January 2001.
Results

Clinical features
A total of 180 infants under 1 year of age at the time of diagnosis were eligible for inclusion in this study. One hundred and eighteen infants had ALL, 38 of whom were treated on the MRC pilot infant protocol and 79 on the modified protocol, with one as previously mentioned who was treated on AML12. Sixty-two infants had myeloid leukaemia, 28 of whom had been treated on AML 10 and 34 on AML 12. No infant in either group had Down syndrome.
The age, gender and leucocyte count at presentation of the infants with ALL and AML are compared in Table 2 . There was no significant difference between the relative proportion of males and females, or of infants younger or older than 6 months of age at diagnosis. Patients with ALL had significantly higher leucocyte counts at presentation than those with AML. 
Cytogenetics
The results of cytogenetic analysis were available for 100 (85%) of the infants with ALL and 57 (92%) of those with AML, as summarised in Table 3 . Among patients with a successful result, there was no evidence of a clonal chromosomal abnormality in nine (9%) infants with ALL and 14 (25%) of those with AML. A rearrangement involving the chromosome band 11q23 was found in 66 (66%) ALL and 20 (35%) AML patients with a successful karyotype. Children with ALL and 11q23 abnormalities were significantly more likely to have CD10-negative B-lineage phenotype (CD19-positive, CD10-negative) (51/66 with vs 8/34 without P = 0.0001). Fourteen of the 20 infants with AML and 11q23 abnormalities had AML M4 or M5 as did 17 of 37 with normal cytogenetics or other abnormalities.
11q23 abnormalities
A summary of the frequency of the different 11q23 abnormalities in ALL and AML is given in Table 4 , while Table 5 provides the karyotypes from those patients in which complex cytogenetic findings involving chromosome 11q23 were identified. These details were only available for children with AML and those with ALL who had been treated on the modified protocol.
Lymphoblastic leukaemia:
The translocation, t(4;11) (q21;q23), was the most common abnormality occurring in 36% of infants with ALL and a successful cytogenetic result, accounting for more than half of those with an abnormality of 11q23. Detailed cytogenetic results were not available for seven patients with t(4;11) from the pilot protocol. In 21 of the 29 patients with complete karyotypes t(4;11) occurred as the sole karyotypic change and in four patients it formed part of a complex rearrangement (Table 5 , Nos 1-4). Additional chromosomal abnormalities were found accompanying t(4;11) in four patients (Nos 5-8) and in two of those with a complex translocation (Nos 1 and 2). In two patients the sole additional abnormality was a translocation involving the short arms of chromosomes 2 and 9 (Nos 5 and 6).
The next most common finding in ALL was the t(11;19)(q23;p13) occurring in 12 patients. No detailed karyotypic information was available for five patients, one of whom had been identified by RT-PCR alone (Table 4 ). In four of the patients with complete karyotypes, t(11;19) was the sole chromosomal change. In one patient there was evidence of a complex translocation, although the third translocation partner was not identified (Table 5 , No. 9). This patient had an extra copy of chromosomes X and 21. The only two other t(11;19) patients with additional abnormalities also had an extra chromosome X (Nos 10 and 11).
Eight patients with ALL had a t(9;11)(p22;q23), although no detailed cytogenetic information was available for two patients. In only one of the six patients with complete karyotypes was an additional abnormality present (No. 12).
The t(10;11)(p12;q23) was seen in five patients with ALL. One had a complex translocation (No. 13), another showed an accompanying abnormality (No. 14) and no detailed cytogenetic information was available for two.
Five infants with ALL had other cytogenetic abnormalities involving 11q23. One showed the t(1;11)(p32;q23) as part of a complex karyotype (No. 15) and a second had a t(11;17)(q23;p13) (No. 16). The karyotype from this patient has been previously reported 12 (patient No. 539). Involvement of the MLL gene in these two patients was confirmed by FISH. One patient with abnormalities of chromosomes 7 and 11 for whom no detailed karyotype was available and a second patient with a normal karyotype were found to have an MLL rearrangement by FISH and were thus included in this group. A patient with a deletion involving 11q23 (No. 17) was also included, although the presence of a rearrangement of MLL had not been tested for.
Myeloid leukaemia:
The most common finding in AML, occurring in 10 patients was t(9;11)(p22;q23) ( Table 4 ). This comprised 50% of patients with AML and an 11q23 abnormality. Two patients showed complex translocations (Table 5 , Nos 18 and 19), one had chromosomal gains accompanying the translocation (No. 20) and two had highly complex karyotypes (Nos 21 and 22). The t(10;11)(p12;q23) was found in four patients. In each case this was the sole karyotypic change. Patient 23 showed an insertion of material from the long arm of chromosome 11 into the short arm of chromosome 10. The t(11;19)(q23;p13) was found in three AML patients as the sole karyotypic abnormality. The t(4;11)(q21;q23) was not seen in the AML group. Other abnormalities involving 11q23 were found in three patients with AML. Two were t(1;11)(p32;q23), as part of a complex karyotype (Nos 24 and 25) and one had t(11;17)(q23;q11 ෂ12) (No. 26).
Other cytogenetic abnormalities (Table 6) Lymphoblastic leukaemia:
Twenty-five percent of children with ALL and a successful cytogenetic result had chromosomal abnormalities other than those involving 11q23. The more unusual complete karyotypes in this group of patients are shown in Table 6 . Five infants had a high hyperdiploid karyotype with 50-56 chromosomes and the classical chromosomal gains. Two of these patients were tested by FISH for the presence of MLL rearrangements and found to be negative. Other non-random abnormalities characteristic of ALL included one t(1;19)(q23;p13), one dic(9;20)(p11ෂ3;q11) and three cases with abnormalities involving the short arm of chromosome 9, two of which had complex karyotypes (Nos 27 Leukemia and 28). Three patients including two with ALL and one with AML showed a t(7;12). In one patient with ALL the t(7;12)(q32;p13) was the sole karyotypic change. The other two cases, one AML and one ALL showed the alternative 7q breakpoint t(7;12)(q36;p13), which can be cryptic. In both of these patients the translocation was associated with trisomy 19. One patient with ALL showed trisomy 8 as the sole abnormality and one showed monosomy 7 (No. 29). There were no cases of Philadelphia chromosome-positive ALL and the frequency of t(12;21)(p13;q22) was unknown as this was tested for and found to be negative in only a small number of patients. The remaining patients with ALL had 46-48 chromosomes with a range of structural changes (Nos 30-36).
Forty per cent of children with AML and a successful cytogenetic result had abnormalities other than those involving 11q23. There were no cases with the good risk chromosomal abnormalities t(8;21)(q22;q22) or t(15;17)(q22;q11), but one patient showed inv(16)(p13q22) in association with trisomy 12. These infants with AML M7 had a t(1;22)(p13;q13). In two of these patients it was the sole abnormality and in the third it was associated with additional chromosomal changes (No. 37). Three patients had abnormalities involving the 8p11 breakpoint, two were t(8;16)(p11;p13) and the third had inv(8)(p11q1) as the sole abnormality. In terms of high risk abnormalities two children who presented with refractory anaemia with excess of blasts (RAEB) had monosomy 7, one as the sole abnormality and one as part of a complex karyotype (No. 38). A complex Figure 1 shows the (EFS) in the two types of leukaemia. EFS (95% confidence intervals) in AML was 60% (47-72%) at 4 years and 6 years, significantly better than that for ALL at 30%
Comparative event-free survival (EFS) in ALL and AML
Figure 1
Event-free survival in infant leukaemia.
(23-39%) at 4 years and 28% (21-37%) at 6 years (P = 0.001).
Similarly, overall survival ( Figure 2 ) is significantly superior at 65% (52-76%) at 4 and 6 years for AML and 41% (32-50%) at 4 years and 37% (29-47%) at 6 years for acute lymphoblastic leukaemia (P = 0.007). The results for infants under 1 year treated on the more recent ALL protocol are better at 4 years with EFS 34% (24-45%) compared with the previous one at 24% EFS (13-39%) (P = 0.054) but both are markedly inferior to that for AML. There is no significant difference in EFS between infants in AML 10 4 year EFS 64% (46-79%) and AML 12 56% (39-72%) (P = 0.6). The difference in EFS between the infants with ALL and AML is due to a significantly lower relapse risk in infants with AML (Table 7) . There is no significant difference in the proportion of early deaths or treatment-related deaths between infants with ALL and AML but there is a highly significant lower rate of relapse in infants with AML. The relapse risk
Figure 2
Survival in infant leukaemia. at 4 years for ALL is 62% (52-71%) and for AML 27% (16-40%) P = 0.0001. Table 8 compares the influence of presenting features on EFS in both types of leukaemia and it can be seen that sex was not found to have a significant influence on prognosis. Age and presenting leucocyte count had a significant influence on outcome in ALL with older infants and those with a low initial leucocyte count having a better prognosis. These factors were not found to be statistically significant in AML but the results were in the same direction. The FAB subtype in patients with AML did not have a significant influence on prognosis. Table 8 also includes a comparison of EFS according to cytogenetic subgroup. There is no significant difference in EFS between patients with normal chromosomes, 11q23 abnormalities and other abnormal findings either in patients with ALL or AML. The 4 year EFS for infants with ALL and normal cytogenetics is 33% (12-64%), for those with t(4;11) 30% (17-46%), with other 11q23 abnormalities 23% (12-41%) and for all other abnormalities 41% (24-61%). The EFS at 4 years for infants with AML and normal cytogenetics is 56% (31-78%), for those with 11q23 abnormalities 55% (34-74%) and those with other abnormalities 64% (43-81%).
781
Since the t(4;11) was seen only in infants with ALL these patients were excluded from analysis and EFS compared for infants with ALL and AML and all other 11q23 abnormalities. Log rank analysis for heterogeneity except presenting WBC, results for trend.
Leukemia
The results are shown in Figure 3 where it can be seen that 4 year EFS for infants with ALL and other 11q23 abnormalities is 23% (12-41%), whereas for AML it is 55% (34-74%) (P = 0.06).
Survival details for other cytogenetic abnormalities
Further analysis of survival data was not performed on other cytogenetically defined groups of patients because the individual numbers were small. The outcome was variable. Tables 5  and 6 provide details of event-free survival in individual patients discussed in the text. Two of the five with high hyperdiploidy remain in remission at 2 and 9 years, two relapsed at 6 months and 2. years and one died in remission at 5 months. The infant with t(1;19) remains in remission at 8 years. Two patients with an abnormality of 9p were in remission at 4 and 5 years but the third relapsed and died at 4 years. Among the patients with AML, the one with inv(16) remains in remission at 70 months as do two of the three with t(1;22). These are alive and well at 84 and 126 months while the third
Figure 3
Event-free survival for infants with 11q23 abnormalities (excluding t(4;11)).
relapsed and died at 10 months from diagnosis. The three patients with breakpoints at 8p11 also remain alive in long remission. One patient with monosomy 7 has died at 3 years and one remains in remission at 5 years. The patient with del(5) and a complex karyotype (case 39) remains in remission at 18 months.
Discussion
Acute leukaemia in infancy is relatively uncommon and uncertainties as to the best treatment approaches persist. In this analysis of 180 infants, treated intensively in a series of UK national trials, it has been possible to compare the clinical and biological features and the response to treatment in infants with ALL and AML. Such comparisons have been rarely performed in recent years due to the small numbers of patients available for study, but are justified in view of the cytogenetic similarities in both types of leukaemia. Our observations, confined to infancy, have extended those from the St Jude Children's Research Hospital which involved young children under the age of 2 years. 13 There was no difference in the age and sex distribution between the two types of leukaemia. However, infants with ALL more frequently presented with higher leucocyte counts than those with AML. They also had a prevalence of early pre-B (CD10-negative) leukaemia, which tended to be associated with cytogenetic abnormalities involving 11q23. The most common subtype of infant AML was monocytic in which 11q23 abnormalities also predominated.
Chromosomal rearrangements involving 11q23 were found in both ALL and AML. They occurred in two-thirds of infants with ALL and just above one-third (35%) of those with AML. The frequency of 11q23 abnormalities in our relatively large unselected series of patients with AML is comparable with that of the series from St Jude 13 but lower than that in other small studies. 14, 15 The 11q23 rearrangements observed here included the majority of the recognised translocations, the most frequent of which was the t(4;11)(q21;q23) in the infants with ALL. This concurs with previous observations that this abnormality occurs almost exclusively in ALL. 16 Some patients with t(4;11) had complex translocations or additional chromosomal abnormalities but the clinical significance of these could not be determined due to the small numbers.
The second most common abnormality occurring in both ALL and AML in this series was the t(9;11)(p22;q23), also noted in the European 11q23 Workshop. 17 Small numbers precluded formal analysis of follow-up in this patient subgroup, but only two of the eight ALL and four of the 10 AML patients remain alive in first remission. This supports the claim that t(9;11) has a worse outcome in infants and perhaps a more favourable outcome in older patients with paediatric AML. 17, 18 The t(11;19)(p13;q23) was seen in both the ALL and AML. The karyotypes were simple in all patients and only three of the ALL patients with complete karyotypes had additional chromosomal abnormalities, which in each case was an X chromosome. Moorman et al 19 had previously made this observation. Unfortunately, detailed information about the partner gene on 19p13 was not available for these patients. The t (11;19) has previously been associated with an extremely poor survival in infants with both ALL and AML. 19 In our series only two of the AML patients remain in remission. The t(10;11)(p12;q23) was observed in both ALL and AML with a poor outcome as previously reported. 20 In addition to the well known translocations, a large number of rare partners to the MLL gene have now been described. 12 In this small series three patients with the t(1;11)(p32;q23) and two with different chromosome 17 breakpoints were found in both the ALL and AML groups. These findings confirm that the range of MLL partners occur, apart from the AF4 gene of the t(4;11), in both ALL and AML and provide supportive evidence that recombination events in infant leukaemia are most likely to occur in cells with multilineage potential. 21 The common cytogenetic abnormalities seen in older children with ALL 22 were under represented in this infant series. There was a small number of patients with high hyperdiploidy or abnormalities of the short arm of chromosome 9 and only one patient had a t(1;19)(q23;p13). Three patients were identified with the recently reported t (7;12) . This rare abnormality appears to occur exclusively in infants with ALL or AML. 23, 24 The translocation usually involves the ETV6 gene at 12p13 with at least two different breakpoints on chromosome 7. In this series t(7;12)(q32;p13) and t(7;12)(q36;p13) were observed. The latter is a rather subtle change, therefore the incidence of t(7;12) may be higher than that reported to date. We found no patients with the Philadelphia chromosome and very limited information was available for the cytogenetically invisible t(12;21)(p13;q22).
These results confirm the overall poor prognosis for infants with ALL, reported in other studies and recently reviewed. 1 It has been claimed that this poor prognosis is associated with the presence of cytogenetic abnormalities, in particular the t(4;11) (25) and/or rearrangements of the MLL gene. 26 However, in this relatively large series of infants we found no significant difference in outcome between infants with t(4;11) and the other patients. Similarly, in a study by the BerlinFrankfurt-Munster group, steroid response was a more important predictor of outcome than cytogenetics. 27 It also appears that abnormalities of 11q23 are associated with a poorer outcome in infants than in older children with ALL. 16, 17, 28 Data from the 11q23 workshop suggested that the t(11;19) is associated with a poor outcome irrespective of age. 19 However, more recent analysis has suggested that older children with the MLL-ENL fusion and t(11;19)(q23;p13.3) translocation do not have a poor prognosis. 29 These findings suggest that factors other than cytogenetics per se influence prognosis. Further large prospective studies are needed to address this issue.
The prognosis in both paediatric and adult AML is strongly influenced by cytogenetics. 30 Only one of the 57 infants with AML studied had a favourable cytogenetic result, namely the inversion of chromosome 16. A small number of patients had unfavourable cytogenetics. These included two patients with monosomy 7 and one with a deletion of the long arm of chromosome 5 within a complex karyotype. Several infants were observed with highly complex karyotypes in which there was no evidence of −7, del(5) or 11q23 abnormalities. Such karyotypes have also been associated with an unfavourable outcome in AML. 30 Surprisingly, a number of these poor risk patients have responded well to treatment. It has also been claimed that the infant-specific abnormalities, t(1;22)(p13;q13) in AML M7 and the t(7;12) in AML and ALL, are associated with an adverse outcome. 24, 31 However, two of the three patients with t(1;22) survive in remission. The two ALL patients with t(7;12) died but the AML patient remains in remission. Our results suggest that cytogenetics may be less predictive of outcome in infants than in older children and adults with AML. Despite the absence of favourable cyto-genetic findings in AML the EFS was very encouraging. Infants with AML treated on the MRC trials AML 10 and 12 have a comparable outcome to older children. 4 Event-free survival and survival were significantly better than for ALL.
The difference in prognosis between ALL and AML was not due to a significant difference in early treatment failure since despite high initial leucocyte counts, which could in theory predispose to early complications, remission was achieved in most cases of ALL. The treatment given for AML was extremely intensive but the risk of induction and remission deaths was no higher than that in infants with ALL. The difference in outcome is due to the relapse risk which at 4 years was 27% in AML and 62% in ALL. The event-free survival in ALL as reported in other series 32 was influenced by age at diagnosis and leucocyte count, but these were not found to be significant in AML.
The difference in prognosis may be attributable in part to the varying proportion of cases with 11q23 abnormalities. However, even the EFS for children with 11q23 abnormalities other than t(4;11) was marginally statistically better in AML than ALL. Other biological properties such as resistance to cell death 33 may perhaps be related to the lineage of the leukaemia and contribute to the difference in outcome.
There is relatively little information available about drug sensitivity and pharmacokinetics in this age group. It has been claimed that blast cells from infants with ALL are relatively more sensitive to cytarabine than those from older children 34 although there is as yet no supportive clinical evidence for this observation. Both protocols incorporated moderate to high doses of cytarabine, albeit with differing schedules. In general, the dose of drugs such as anthracyclines given in the two types of protocol was similar, although the second intensification protocol in AML was far more intensive. There is scope for more intensified therapy during the first few months of treatment for ALL. International trials will be needed to evaluate the efficacy of this approach.
